JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Velikyan, I.
Right arrow Articles by Tolmachev, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Velikyan, I.
Right arrow Articles by Tolmachev, V.
Journal of Nuclear Medicine Vol. 46 No. 11 1881-1888
© 2005 by Society of Nuclear Medicine


Basic Science Investigations

Preparation and Evaluation of 68Ga-DOTA-hEGF for Visualization of EGFR Expression in Malignant Tumors

Irina Velikyan, PhD1,2, Åsa Liljegren Sundberg, PhD3, Örjan Lindhe, PhD2, A. Urban Höglund, PhD2, Olof Eriksson, MS2, Eva Werner, MS2, Jorgen Carlsson, PhD3, Mats Bergström, PhD2, Bengt Långström, PhD1,2 and Vladimir Tolmachev, PhD3

1 Department of Organic Chemistry, Institute of Chemistry, Biomedical Centre, Uppsala University, Uppsala, Sweden
2 Uppsala Imanet AB, Uppsala, Sweden
3 Division of Biomedical Radiation Sciences, Uppsala University, Uppsala, Sweden

Detection of epidermal growth factor receptor (EGFR) overexpression in many carcinomas provides important diagnostic information, which can influence patient management. The use of PET may enable such detection in vivo by a noninvasive procedure with high sensitivity. The aim of this study was to develop a method for preparation of a positron-emitting tracer based on a natural ligand to EGFR, the recombinant human epidermal growth factor (hEGF), and to perform a preclinical evaluation of the tracer. Methods: DOTA-hEGF (DOTA is 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid) was prepared by coupling of a N-sulfosuccinimide ester of DOTA to hEGF. The conjugate was labeled with a generator-produced positron-emitting nuclide, 68Ga (half-life = 68 min), using microwave heating. Binding specificity, affinity, internalization, and retention of 68Ga-DOTA-hEGF was studied in 2 EGFR-expressing cell lines, U343 glioma cells and A431 cervical carcinoma cells. Biodistribution and microPET visualization studies were performed in BALB/c nu/nu mice bearing A431 carcinoma xenografts. Results: A 1-min-long microwave-assisted labeling provided radioactivity incorporation of 77% ± 4%. Both cell lines demonstrated receptor-specific uptake of the conjugate, rapid internalization of the tracer, and good retention of radioactivity. Binding to both cell lines occurred with high affinity, approximately 2 nmol/L. The biodistribution study demonstrated accumulation of radioactivity in xenografts and in EGFR-expressing organs. The microPET imaging study enabled visualization of tumors and demonstrated quick—within 5 min—localization of radioactivity in tumors. Conclusion: 68Ga-DOTA-hEGF has potential for imaging EGFR overexpression in tumors.

Key Words: 68Ga • epidermal growth factor • PET • microPET • malignant tumors


Related articles in JNM:

THIS MONTH IN JNM

JNM 2005 46: 7a-8a. [Full Text]  



This article has been cited by other articles:


Home page
Ann OncolHome page
M. A. Pantaleo, M. Nannini, A. Maleddu, S. Fanti, C. Nanni, S. Boschi, F. Lodi, G. Nicoletti, L. Landuzzi, P. L. Lollini, et al.
Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer
Ann. Onc., February 1, 2009; 20(2): 213 - 226.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
V. Tolmachev, M. Friedman, M. Sandstrom, T. L.J. Eriksson, D. Rosik, M. Hodik, S. Stahl, F. Y. Frejd, and A. Orlova
Affibody Molecules for Epidermal Growth Factor Receptor Targeting In Vivo: Aspects of Dimerization and Labeling Chemistry
J. Nucl. Med., February 1, 2009; 50(2): 274 - 283.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
D. A. Mankoff, J. M. Link, H. M. Linden, L. Sundararajan, and K. A. Krohn
Tumor Receptor Imaging
J. Nucl. Med., June 1, 2008; 49(Suppl_2): 149S - 163S.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
L. O. T. Gainkam, L. Huang, V. Caveliers, M. Keyaerts, S. Hernot, I. Vaneycken, C. Vanhove, H. Revets, P. De Baetselier, and T. Lahoutte
Comparison of the Biodistribution and Tumor Targeting of Two 99mTc-Labeled Anti-EGFR Nanobodies in Mice, Using Pinhole SPECT/Micro-CT
J. Nucl. Med., May 1, 2008; 49(5): 788 - 795.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2005 by the Society of Nuclear Medicine.